Trial Profile
An prospective, open-label, random and control clinical trail of Apatinib combined with TACE contrast to the simple TACE in the treatment of recurrent hepatocellular carcinoma (HCC)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 04 Jul 2020 Primary endpoint (PFS) has been met as per the results presented at the 22nd World Congress on Gastrointestinal Cancer.
- 04 Jul 2020 Results presented at the 22nd World Congress on Gastrointestinal Cancer
- 19 Sep 2017 New trial record